Photobiomodulation for Parkinson’s Disease in Animal Models: A Systematic Review

Salehpour, Farzad; Hamblin, Michael R.

doi:10.3390/biom10040610

Cited by 52 publications

(41 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the past few decades, PBM treatment has shown beneficial effects on multiple brain disorders in animal models and in limited human studies including ischemic stroke 67 , 68 , Parkinson's disease 69 , Alzheimer's disease 30 , depression 70 , and anxiety 71 . According to previous studies, laser wavelengths in the red (i.e., 600-700 nm) and near-infrared (NIR, 760-1200 nm) range are the most commonly used wavelengths for PBM medical applications 26 , 72 , 73 .…”

Section: Discussionmentioning

confidence: 99%

Effects of prenatal photobiomodulation treatment on neonatal hypoxic ischemia in rat offspring

Yang¹,

Dong²,

Wu³

et al. 2021

Theranostics

View full text Add to dashboard Cite

Neonatal hypoxic-ischemic (HI) injury is a severe complication often leading to neonatal death and long-term neurobehavioral deficits in children. Currently, the only treatment option available for neonatal HI injury is therapeutic hypothermia. However, the necessary specialized equipment, possible adverse side effects, and limited effectiveness of this therapy creates an urgent need for the development of new HI treatment methods. Photobiomodulation (PBM) has been shown to be neuroprotective against multiple brain disorders in animal models, as well as limited human studies. However, the effects of PBM treatment on neonatal HI injury remain unclear. Methods: Two-minutes PBM (808 nm continuous wave laser, 8 mW/cm 2 on neonatal brain) was applied three times weekly on the abdomen of pregnant rats from gestation day 1 (GD1) to GD21. After neonatal right common carotid artery ligation, cortex- and hippocampus-related behavioral deficits due to HI insult were measured using a battery of behavioral tests. The effects of HI insult and PBM pretreatment on infarct size; synaptic, dendritic, and white matter damage; neuronal degeneration; apoptosis; mitochondrial function; mitochondrial fragmentation; oxidative stress; and gliosis were then assessed. Results: Prenatal PBM treatment significantly improved the survival rate of neonatal rats and decreased infarct size after HI insult. Behavioral tests revealed that prenatal PBM treatment significantly alleviated cortex-related motor deficits and hippocampus-related memory and learning dysfunction. In addition, mitochondrial function and integrity were protected in HI animals treated with PBM. Additional studies revealed that prenatal PBM treatment significantly alleviated HI-induced neuroinflammation, oxidative stress, and myeloid cell/astrocyte activation. Conclusion: Prenatal PBM treatment exerts neuroprotective effects on neonatal HI rats. Underlying mechanisms for this neuroprotection may include preservation of mitochondrial function, reduction of inflammation, and decreased oxidative stress. Our findings support the possible use of PBM treatment in high-risk pregnancies to alleviate or prevent HI-induced brain injury in the perinatal period.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of prenatal photobiomodulation treatment on neonatal hypoxic ischemia in rat offspring

Yang¹,

Dong²,

Wu³

et al. 2021

Theranostics

View full text Add to dashboard Cite

show abstract

“…To date over 30 in vitro and in vivo studies of PBM in PD models have explored variations on the theme (Hong, 2019;Salehpour and Hamblin, 2020). The most comprehensive and compelling research on the neuroprotective effect of PBM in PD has come from studies of transcranial and intracranial PBM in chemically-induced rodents (Peoples et al, 2012;Shaw et al, 2012;Moro et al, 2013Moro et al, , 2014Purushothuman et al, 2013;O'Callaghan et al, 2015;Reinhart et al, 2015Reinhart et al, , 2016aReinhart et al, 2017) and non-human primate PD models (Moro et al, 2016(Moro et al, , 2017El Massri et al, 2017).…”

Section: Photobiomodulationmentioning

confidence: 99%

Targeting Mitochondrial Impairment in Parkinson's Disease: Challenges and Opportunities

Prasuhn

Davis

Kumar

2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The underlying pathophysiology of Parkinson's disease is complex, but mitochondrial dysfunction has an established and prominent role. This is supported by an already large and rapidly growing body of evidence showing that the role of mitochondrial (dys)function is central and multifaceted. However, there are clear gaps in knowledge, including the dilemma of explaining why inherited mitochondriopathies do not usually present with parkinsonian symptoms. Many aspects of mitochondrial function are potential therapeutic targets, including reactive oxygen species production, mitophagy, mitochondrial biogenesis, mitochondrial dynamics and trafficking, mitochondrial metal ion homeostasis, sirtuins, and endoplasmic reticulum links with mitochondria. Potential therapeutic strategies may also incorporate exercise, microRNAs, mitochondrial transplantation, stem cell therapies, and photobiomodulation. Despite multiple studies adopting numerous treatment strategies, clinical trials to date have generally failed to show benefit. To overcome this hurdle, more accurate biomarkers of mitochondrial dysfunction are required to detect subtle beneficial effects. Furthermore, selecting study participants early in the disease course, studying them for suitable durations, and stratifying them according to genetic and neuroimaging findings may increase the likelihood of successful clinical trials. Moreover, treatments involving combined approaches will likely better address the complexity of mitochondrial dysfunction in Parkinson's disease. Therefore, selecting the right patients, at the right time, and using targeted combination treatments, may offer the best chance for development of an effective novel therapy targeting mitochondrial dysfunction in Parkinson's disease.

show abstract

“…The interplay between the microbiome and the central nervous system has given birth to a new attractive field of scientific research—that of neuromicrobiology. This domain studies the activity of the intestinal–brain axis and the correlation between the microbiome and related pathologies [ 261 ], as well as looking to design active applications to fit the effects of the microbiome on the central nervous system, such as for example the probiotics, photobiomodulation, and the brain, in humans or animal models [ 262 ].…”

Section: Photobiomodulation Applied On the Gut–lung–brain Axismentioning

confidence: 99%

“…PBM could correct the disturbances in the mitochondrial energetic metabolism of the intestinal neurons, adjusting the synaptic transmission and the cell secretion, and reinstalling the correct bidirectional transfer of information on the gut–brain axis; so, PBM is a recent and very promising non-pharmacological treatment modality for dysfunctions and diseases on this axis [ 262 , 270 ].…”

Section: Photobiomodulation Applied On the Gut–lung–brain Axismentioning

confidence: 99%

Probiotics, Photobiomodulation, and Disease Management: Controversies and Challenges

Ailioaie

Litscher

2021

IJMS

View full text Add to dashboard Cite

In recent decades, researchers around the world have been studying intensively how micro-organisms that are present inside living organisms could affect the main processes of life, namely health and pathological conditions of mind or body. They discovered a relationship between the whole microbial colonization and the initiation and development of different medical disorders. Besides already known probiotics, novel products such as postbiotics and paraprobiotics have been developed in recent years to create new non-viable micro-organisms or bacterial-free extracts, which can provide benefits to the host with additional bioactivity to probiotics, but without the risk of side effects. The best alternatives in the use of probiotics and postbiotics to maintain the health of the intestinal microbiota and to prevent the attachment of pathogens to children and adults are highlighted and discussed as controversies and challenges. Updated knowledge of the molecular and cellular mechanisms involved in the balance between microbiota and immune system for the introspection on the gut–lung–brain axis could reveal the latest benefits and perspectives of applied photobiomics for health. Multiple interconditioning between photobiomodulation (PBM), probiotics, and the human microbiota, their effects on the human body, and their implications for the management of viral infectious diseases is essential. Coupled complex PBM and probiotic interventions can control the microbiome, improve the activity of the immune system, and save the lives of people with immune imbalances. There is an urgent need to seek and develop innovative treatments to successfully interact with the microbiota and the human immune system in the coronavirus crisis. In the near future, photobiomics and metabolomics should be applied innovatively in the SARS-CoV-2 crisis (to study and design new therapies for COVID-19 immediately), to discover how bacteria can help us through adequate energy biostimulation to combat this pandemic, so that we can find the key to the hidden code of communication between RNA viruses, bacteria, and our body.

show abstract

Photobiomodulation for Parkinson’s Disease in Animal Models: A Systematic Review

Cited by 52 publications

References 58 publications

Effects of prenatal photobiomodulation treatment on neonatal hypoxic ischemia in rat offspring

Effects of prenatal photobiomodulation treatment on neonatal hypoxic ischemia in rat offspring

Targeting Mitochondrial Impairment in Parkinson's Disease: Challenges and Opportunities

Probiotics, Photobiomodulation, and Disease Management: Controversies and Challenges

Contact Info

Product

Resources

About